In the January 2017 issue, the piece “Living therapeutics: Scientists genetically modify bacteria to deliver drugs” (Nat. Med 23, 5–7, 2017) incorrectly stated that the company Oragenics is slated to launch a phase 2 trial on ulcerative mucositis next year. In fact, they will begin the trial in 2017. The error has been corrected in the HTML and PDF versions of this article.
Additional information
The online version of the original article can be found at 10.1038/nm0117-5
Rights and permissions
About this article
Cite this article
Correction. Nat Med 23, 269 (2017). https://doi.org/10.1038/nm0317-269
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0317-269